Patents by Inventor David P. Steensma

David P. Steensma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Erythropoietic stimulating agent (ESA) dosage determination
    Patent number: 11410744
    Abstract: An Erythropoietic Stimulating Agent (ESA) dosing system/method determines patient-specific ESA therapies for patients affected by insufficient hemoglobin production that may benefit from ESA treatment. The ESA dosing system includes a model that represents a process by which red blood cells are produced in humans. The model may include one or more parameters, the values of which are patient-specific. The model takes into account patient-specific historical hemoglobin (Hgb) data and corresponding historical ESA dosage data to estimate the patient-specific values of the model parameters, and determines a target therapeutic dose of the ESA that may maintain the patient's Hgb within a target range.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: August 9, 2022
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Craig L. Hocum, James T. McCarthy, David P. Steensma, David Dingli, Edward J. Gallaher, James L. Rogers
  • ERYTHROPOIETIC STIMULATING AGENT (ESA) DOSAGE DETERMINATION
    Publication number: 20180218110
    Abstract: An Erythropoietic Stimulating Agent (ESA) dosing system/method determines patient-specific ESA therapies for patients affected by insufficient hemoglobin production that may benefit from ESA treatment. The ESA dosing system includes a model that represents a process by which red blood cells are produced in humans. The model may include one or more parameters, the values of which are patient-specific. The model takes into account patient-specific historical hemoglobin (Hgb) data and corresponding historical ESA dosage data to estimate the patient-specific values of the model parameters, and determines a target therapeutic dose of the ESA that may maintain the patient's Hgb within a target range.
    Type: Application
    Filed: March 22, 2018
    Publication date: August 2, 2018
    Inventors: Craig L. Hocum, James T. McCarthy, David P. Steensma, David Dingli, Edward J. Gallaher, James L. Rogers
  • ERYTHROPOIETIC STIMULATING AGENT (ESA) DOSAGE DETERMINATION
    Publication number: 20130191097
    Abstract: An Erythropoietic Stimulating Agent (ESA) dosing system/method determines patient-specific ESA therapies for patients affected by insufficient hemoglobin production that may benefit from ESA treatment. The ESA dosing system includes a model that represents a process by which red blood cells are produced in humans. The model may include one or more parameters, the values of which are patient-specific. The model takes into account patient-specific historical hemoglobin (Hgb) data and corresponding historical ESA dosage data to estimate the patient-specific values of the model parameters, and determines a target therapeutic dose of the ESA that may maintain the patient's Hgb within a target range.
    Type: Application
    Filed: January 4, 2011
    Publication date: July 25, 2013
    Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Craig L. Hocum, James T. McCarthy, David P. Steensma, David Dingli, James L. Rogers, Edward J. Gallaher